Anti-JAM-A/F11R Antibody, clone CSTEM27

Junctional adhesion molecule A (UniProt: Q9Y624; also known as JAM-A, Junctional adhesion molecule 1, JAM-1, Platelet F11 receptor, Platelet adhesion molecule 1, PAM-1, CD321) is encoded by the F11R (also known as JAM1, JCAM) gene (Gene ID: 50848) in human. JAM-A/F11R is a single-pass type I membrane protein that is localized at tight junctions of both epithelial and endothelial cells. It is also expressed in circulating platelets and leukocytes. It is synthesized with a signal peptide (aa 1-27), which is subsequently cleaved off to produce the mature form that contains an extracellular domain (aa 28-238), a transmembrane domain (aa 239-259), and a cytoplasmic domain (aa 260-299). The extracellular domain contains a membrane distal VH-type Ig-like domain (D1; aa 28-125) and a membrane proximal C2-type Ig-like domain (D2; aa 135-228) that contains a single glycosylation site (Asn 185). The cytoplasmic domain includes two phosphorylation sites (Tyr 280 and Ser 284) and also has a type II PDZ domain-binding motif (aa 297-299). JAM-A/F11R plays a role in epithelial tight junction formation and also regulates monocyte transmigration involved in integrity of epithelial barrier. It participates in the regulation of various biological processes, including paracellular permeability, tight junction formation and maintenance, leukocyte trans-endothelial migration, epithelial-to-mesenchymal transition (EMT), angiogenesis, reovirus binding, and platelet activation. Its dysregulation may contribute to pathological consequences, such as cardiovascular diseases, inflammatory bowel disease, neurological disorders, and various cancer types. In cancer cells, it is not only associated with regulation of cell migration, but it also affects apoptosis, EMT, cancer stem cell maintenance, and cell proliferation. Down-regulation of JAM-A/F11R results in elevated cell migration, invasion, and metastasis in various breast cancer cell lines. Its higher levels have been linked to reduced cell migration ability of cancer cells. (Ref.: Czubak-Prowizor, K., et al. (2022). Mol. Cell. Biochem. 477(1); 79-98; Liu, X., et al. (2020). Nature. 586(7827); 101-107).

Clone CSTEM27 is a mouse monoclonal antibody that detects Junctional adhesion molecule A (JAM-A/FR11). It targets an epitope within the extracellular domain.

His-tagged recombinant fragment corresponding to the extracellular domain of human Junctional adhesion molecule A (JAM-A/F11R).

Quality Control Testing

Evaluated by Western Blotting with recombinant Human JAM-A/F11R protein.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected recombinant Human JAM-A/F11R protein.

Tested Applications

Flow Cytometry Analysis: A representative lot detected JAM-A/F11R in Flow Cytometry application (Liu, X., et al. (2017). Nat Methods. 14(11); 1055-1062; O Brien, C.M., et al. (2017). Stem Cells. 35(3); 626-640; Liu, X., et al. (2020). Nature. 586(7827); 101-107).

ELISA Analysis: A representative lot detected JAM-A/F11R in ELISA application (O Brien, C.M., et al. (2017). Stem Cells. 35(3); 626-640).

Immunocytochemistry Analysis: A representative lot detected JAM-A/F11R in Immunocytochemistry application (O Brien, C.M., et al. (2017). Stem Cells. 35(3); 626-640).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-JAM-A/F11R, clone CSTEM27, Cat. No. MABT1541, is a mouse monoclonal antibody that detects Junctional adhesion molecule A (JAM-A/FR11) and is tested for use in ELISA, Flow Cytometry, Immunocytochemistry, and Western Blotting.

Purified mouse monoclonal antibody IgG2a in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.